CompaniesMedGenome

MedGenome

defunct
About

Defunct Company

Areas of Focus

Categories

Rebranded/RenamedBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (1)
View all

Total Trials

1

As Lead Sponsor

0

As Collaborator

1

Total Enrollment

81

By Phase

PHASE2: 1

By Status

COMPLETED: 1
Clinical Trials Pipeline1 trial
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Today
NCT02553642
Hover over trial bars to see details

Recent Trials

NCT02553642Collaborator
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
PHASE2Completed
81 participants
Started: Sep 14, 2015 · Completed: Apr 29, 2024